Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Janssen Biotech (Details)

v3.22.2
Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2021
May 31, 2021
Aug. 31, 2019
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2019
Licensing and other arrangements                
Revenue from contracts with customers       $ 525 $ 525 $ 3,275 $ 544  
Janssen Biotech Inc. | License Agreement                
Licensing and other arrangements                
Cash payment received     $ 2,500          
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events     $ 3,000          
Percentage of royalty on worldwide net sales of each product upon commercialization     0.75%          
Revenue from contracts with customers $ 200 $ 500   0 $ 500 0 $ 500 $ 2,500
Contract assets 0     0   0    
Contract liabilities 0     0   0    
Capitalized contract costs $ 0     $ 0   $ 0